ArticleJournal of natural medicines2026
New meroterpenoids from Sargassum macrocarpum as inhibitors of amyloid β aggregation.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Four Undescribed Chromane-Type Meroterpenoids From Sargassum siliquastrum and Their Inhibitory Activity Against Amyloid-β42 Aggregation.Chemistry & biodiversity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Three new meroterpenoids, macrocarquinoids J(1)–L(3) were isolated from brown alga, Sargassum macrocarpum, along with sargahydroquinoic acid. The structures of 1–3 were elucidated with 2D NMR spectral data. The inhibitory activities of these compounds against Aβ42 aggregation were evaluated using thioflavin T assay and transmission electron microscopy. All three new meroterpenoids were found to be active, and macrocarquinoid L was the strongest among the three compounds. Furthermore, sargahydroquinoic acid significantly delayed the onset of paralysis in transgenic Caenorhabditis elegans, suggesting its potential inhibitory effect on amyloid aggregation.
Indexed as
Identifiers
41801297What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.